Imaging Agents Market by Agent Type (Gadolinium Based Agents, Iodinated Contrast Agents, Microbubble Agents), Modality (Computed Tomography, Magnetic Resonance Imaging, Nuclear Imaging), Application, End User, Distribution Channel - Global Forecast 2025-2
Description
The Imaging Agents Market was valued at USD 10.17 billion in 2024 and is projected to grow to USD 10.76 billion in 2025, with a CAGR of 5.82%, reaching USD 15.99 billion by 2032.
Establishing the Foundation for a Dynamic Imaging Agents Market Fueled by Technological Innovations Evolving Clinical Needs and Strategic Partnerships
Imaging agents lie at the heart of modern diagnostics, empowering clinicians to visualize physiological processes and detect pathologies with unprecedented clarity. These specialized compounds, whether based on gadolinium, iodine, microbubbles, or radiopharmaceuticals, bridge the gap between complex biological systems and actionable medical data. As healthcare providers strive to enhance patient outcomes and precision medicine initiatives, the role of contrast media and targeted tracers has never been more critical.
Against this backdrop, the imaging agents landscape is being reshaped by technological breakthroughs and evolving clinical imperatives. This executive summary synthesizes key developments across regulatory frameworks, supply chain dynamics, and segmentation nuances. It illuminates transformative shifts in modality preferences, dissects the ramifications of recent tariffs, and lays out tailored recommendations for stakeholders. With a focus on strategic clarity and operational readiness, this overview sets the stage for deeper exploration into segmentation insights, regional dynamics, competitive positioning, and research methodologies that underpin robust decision-making.
Revolutionary Disruptions Reshaping the Imaging Agents Ecosystem with AI Integration Novel Contrast Modalities and Regulatory Overhauls Driving Future Development
The imaging agents sector is undergoing unprecedented transformation as artificial intelligence algorithms refine image acquisition and contrast optimization. AI-driven reconstruction techniques are enabling lower dose protocols while preserving diagnostic confidence. Concurrently, the introduction of novel contrast modalities, including hybrid fluorophore-nanoparticle complexes, is opening pathways for enhanced molecular targeting and theranostic applications.
Regulatory agencies are adapting to these innovations by accelerating review processes and issuing guidance on safety and efficacy standards for next-generation agents. This shift towards more flexible frameworks is encouraging collaboration between biotech firms and academic research institutes, fostering environments where rapid prototyping and iterative clinical testing can take place. Meanwhile, strategic partnerships between imaging vendors and contract research organizations are smoothing the transition from bench to bedside. As a result, stakeholders must remain vigilant in monitoring evolving compliance requirements and invest in modular platforms that accommodate future enhancements.
Assessing the Ripple Effects of Recent United States Tariffs on Global Imaging Agents Trade Patterns Supply Chains and Cost Structures Through 2025
The introduction of broad‐based import duties on key reagents and precursor compounds has created a ripple effect across the imaging agents supply chain. Manufacturers that historically sourced gadolinium salts, iodine derivatives, and radiolabeling isotopes from specific international suppliers are now recalibrating procurement strategies. Many are exploring near-shoring options or vertically integrating upstream processes to maintain cost predictability and secure uninterrupted access to critical raw materials.
In response, distributors and direct sales teams are renegotiating contracts and adjusting pricing structures to offset incremental tariff burdens. These adaptations have prompted an industry-wide dialogue on supply chain resilience, encouraging organizations to diversify supplier pools and establish contingency inventory. Although short-term cost pressures are evident, the concerted pursuit of alternative sourcing pathways and streamlined logistics is laying the groundwork for long-term stability and efficiency improvements.
Unveiling Segmentation Insights Spanning Agent Types Imaging Modalities Clinical Applications Distribution Channels Shaping Targeted Market Approaches
Deep segmentation analysis reveals distinct pockets of opportunity and competitive intensity across agent type, modality, application, end user, and distribution paradigms. Contrast media rooted in gadolinium exhibit robust adoption within magnetic resonance imaging, while iodinated agents remain indispensable to computed tomography procedures. Microbubble formulations have carved out a niche in ultrasound imaging, particularly where three-dimensional visualization enhances diagnostic confidence. Concurrently, radiopharmaceuticals span diverse needs, with PET imaging agents gaining traction for oncology staging and SPECT tracers reinforcing neurology and cardiology workflows.
From a modality perspective, the interplay between computed tomography, magnetic resonance imaging, nuclear imaging, and ultrasound underscores the importance of portfolio breadth. Nuclear imaging bifurcates into PET and SPECT pathways, each demanding tailored tracer chemistry. Ultrasound diverges into two-dimensional and three-dimensional agent variants, capitalizing on real-time imaging dynamics. On the application front, cardiology and oncology remain the most active segments, yet gastroenterology, musculoskeletal, and neurology procedures are fueling incremental uptake. End user profiles span academic research institutes to ambulatory surgical centers, diagnostic laboratories, and hospitals and imaging centers. Distribution channels encompass direct sales teams, international and local distributors, and emerging online retail platforms that are reshaping customer engagement and fulfillment models.
Deciphering Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific to Reveal Growth Drivers and Strategic Investment Hotspots
Regional dynamics offer a nuanced perspective on where demand, innovation, and infrastructure converge to create competitive advantages. In the Americas, advanced healthcare systems and established reimbursement pathways support rapid adoption of high-end contrast media and radiopharmaceutical agents. North American research hubs continue to pioneer novel tracer development, while Latin American markets are investing in capacity expansion to broaden patient access.
In Europe, Middle East & Africa, a patchwork of regulatory regimes and reimbursement policies influences launch strategies and pricing. Western European nations maintain stringent approval processes balanced by structured market access programs, whereas Gulf Cooperation Council countries are investing heavily in nuclear imaging infrastructure. Africa presents emerging opportunities for portable ultrasound contrast agents in regions underserved by centralized imaging facilities. Across the Asia-Pacific, robust population growth, improving healthcare expenditure, and local manufacturing initiatives are driving dynamic uptake. From established economies in Japan and Australia to rapidly expanding markets in China and India, stakeholders are tailoring portfolios to align with regional epidemiology and resource availability.
Analyzing Competitive Strategies and Innovation Benchmarks of Leading Market Players Driving Technological Leadership and Portfolio Differentiation in Imaging Agent Development
Leading stakeholders in the imaging agents domain are leveraging robust R&D pipelines, strategic alliances, and targeted acquisitions to maintain competitive differentiation. Established multinationals are prioritizing molecular innovation and supply chain integration, while nimble biotechs are capitalizing on niche therapeutic areas and orphan indications. Collaborative ventures between major healthcare conglomerates and specialized tracer developers are expediting clinical trials and broadening geographic reach.
Companies are also emphasizing portfolio diversification, balancing traditional contrast media lines with emerging microbubble and radiopharmaceutical offerings. The integration of digital platforms for remote training, quality assurance, and predictive maintenance enhances customer engagement and fosters long-term loyalty. Intellectual property strategies center on novel chelates, biodegradable carriers, and advanced radiolabeling methodologies. As competitive intensity intensifies, the ability to align technological prowess with market access acumen will define leadership positions.
Implementing Strategic Imperatives for Industry Leaders to Leverage Emerging Imaging Agent Technologies Optimize Supply Networks and Expand Global Footprint
To capitalize on emerging opportunities, industry leaders should accelerate investments in artificial intelligence-enabled agent design and predictive analytics. Establishing cross-functional teams that integrate chemistry, data science, and regulatory expertise will shorten development timelines and enhance product profiles. At the same time, formalizing partnerships with contract manufacturing organizations and raw material suppliers can mitigate tariff risks and bolster supply chain agility.
Additionally, fostering collaborations with academic research institutes will unlock early‐stage discoveries and facilitate seamless translation to clinical practice. Embracing decentralized manufacturing models and localized production hubs will reduce lead times and support personalized medicine initiatives. Ultimately, organizations that align strategic prioritization with operational excellence and regulatory foresight will be best positioned to drive sustainable growth.
Applying Rigorous Research Methodologies Integrating Primary Interviews Secondary Data Analysis and Multi Layered Validation for Market Intelligence
This analysis is underpinned by a rigorous, multi-source research framework designed to deliver comprehensive market intelligence. Primary insights were garnered through in-depth interviews with key opinion leaders in radiology, nuclear medicine, and healthcare policy, supplemented by discussions with supply chain directors and commercial strategists. These first-hand perspectives provided actionable context on evolving clinical practices, sourcing challenges, and adoption barriers.
Secondary data collection encompassed peer-reviewed publications, regulatory filings, company financial reports, and public health databases. Through meticulous data synthesis and cross-validation, trends were corroborated and discrepancies resolved. The resulting narrative was subjected to multi-layered validation workshops with industry experts to ensure accuracy, relevance, and clarity. This structured approach ensures that the conclusions and recommendations presented herein rest on a solid evidentiary foundation.
Synthesizing Strategic and Analytical Insights to Navigate the Evolving Imaging Agents Landscape with Confidence Competitive Edge and Informed Decision Making
The imaging agents landscape is in the midst of a profound evolution, driven by converging technological, regulatory, and supply dynamics. From advanced contrast media formulations to precision radiopharmaceutical tracers, stakeholders face both unprecedented opportunities and complex challenges. Successful navigation requires a clear understanding of segmentation nuances, regional variances, and competitive imperatives.
By synthesizing transformative shifts, tariff impacts, segmentation insights, and best‐in‐class company strategies, this executive summary provides a cohesive roadmap for informed decision-making. Organizations that adopt a proactive stance-embracing innovation, fortifying supply chains, and forging strategic alliances-will secure a decisive advantage in this rapidly evolving arena.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Agent Type
Gadolinium Based Agents
Iodinated Contrast Agents
Microbubble Agents
Radiopharmaceuticals
Pet Imaging Agents
Spect Imaging Agents
Modality
Computed Tomography
Magnetic Resonance Imaging
Nuclear Imaging
Pet Imaging Agents
Spect Imaging Agents
Ultrasound Imaging
Three D Imaging Agents
Two D Imaging Agents
Application
Cardiology
Gastroenterology
Musculoskeletal
Neurology
Oncology
End User
Academic Research Institutes
Ambulatory Surgical Centers
Diagnostic Laboratories
Hospitals And Imaging Centers
Distribution Channel
Direct Sales
Distributors
International Distributors
Local Distributors
Online Retail
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
GE Healthcare
Bayer AG
Bracco Imaging S.p.A.
Guerbet S.A.
Lantheus Holdings, Inc.
Siemens Healthineers AG
Mallinckrodt plc
Fujifilm Holdings Corporation
Sagent Pharmaceuticals, Inc.
Cardinal Health, Inc.
Note: PDF & Excel + Online Access - 1 Year
Establishing the Foundation for a Dynamic Imaging Agents Market Fueled by Technological Innovations Evolving Clinical Needs and Strategic Partnerships
Imaging agents lie at the heart of modern diagnostics, empowering clinicians to visualize physiological processes and detect pathologies with unprecedented clarity. These specialized compounds, whether based on gadolinium, iodine, microbubbles, or radiopharmaceuticals, bridge the gap between complex biological systems and actionable medical data. As healthcare providers strive to enhance patient outcomes and precision medicine initiatives, the role of contrast media and targeted tracers has never been more critical.
Against this backdrop, the imaging agents landscape is being reshaped by technological breakthroughs and evolving clinical imperatives. This executive summary synthesizes key developments across regulatory frameworks, supply chain dynamics, and segmentation nuances. It illuminates transformative shifts in modality preferences, dissects the ramifications of recent tariffs, and lays out tailored recommendations for stakeholders. With a focus on strategic clarity and operational readiness, this overview sets the stage for deeper exploration into segmentation insights, regional dynamics, competitive positioning, and research methodologies that underpin robust decision-making.
Revolutionary Disruptions Reshaping the Imaging Agents Ecosystem with AI Integration Novel Contrast Modalities and Regulatory Overhauls Driving Future Development
The imaging agents sector is undergoing unprecedented transformation as artificial intelligence algorithms refine image acquisition and contrast optimization. AI-driven reconstruction techniques are enabling lower dose protocols while preserving diagnostic confidence. Concurrently, the introduction of novel contrast modalities, including hybrid fluorophore-nanoparticle complexes, is opening pathways for enhanced molecular targeting and theranostic applications.
Regulatory agencies are adapting to these innovations by accelerating review processes and issuing guidance on safety and efficacy standards for next-generation agents. This shift towards more flexible frameworks is encouraging collaboration between biotech firms and academic research institutes, fostering environments where rapid prototyping and iterative clinical testing can take place. Meanwhile, strategic partnerships between imaging vendors and contract research organizations are smoothing the transition from bench to bedside. As a result, stakeholders must remain vigilant in monitoring evolving compliance requirements and invest in modular platforms that accommodate future enhancements.
Assessing the Ripple Effects of Recent United States Tariffs on Global Imaging Agents Trade Patterns Supply Chains and Cost Structures Through 2025
The introduction of broad‐based import duties on key reagents and precursor compounds has created a ripple effect across the imaging agents supply chain. Manufacturers that historically sourced gadolinium salts, iodine derivatives, and radiolabeling isotopes from specific international suppliers are now recalibrating procurement strategies. Many are exploring near-shoring options or vertically integrating upstream processes to maintain cost predictability and secure uninterrupted access to critical raw materials.
In response, distributors and direct sales teams are renegotiating contracts and adjusting pricing structures to offset incremental tariff burdens. These adaptations have prompted an industry-wide dialogue on supply chain resilience, encouraging organizations to diversify supplier pools and establish contingency inventory. Although short-term cost pressures are evident, the concerted pursuit of alternative sourcing pathways and streamlined logistics is laying the groundwork for long-term stability and efficiency improvements.
Unveiling Segmentation Insights Spanning Agent Types Imaging Modalities Clinical Applications Distribution Channels Shaping Targeted Market Approaches
Deep segmentation analysis reveals distinct pockets of opportunity and competitive intensity across agent type, modality, application, end user, and distribution paradigms. Contrast media rooted in gadolinium exhibit robust adoption within magnetic resonance imaging, while iodinated agents remain indispensable to computed tomography procedures. Microbubble formulations have carved out a niche in ultrasound imaging, particularly where three-dimensional visualization enhances diagnostic confidence. Concurrently, radiopharmaceuticals span diverse needs, with PET imaging agents gaining traction for oncology staging and SPECT tracers reinforcing neurology and cardiology workflows.
From a modality perspective, the interplay between computed tomography, magnetic resonance imaging, nuclear imaging, and ultrasound underscores the importance of portfolio breadth. Nuclear imaging bifurcates into PET and SPECT pathways, each demanding tailored tracer chemistry. Ultrasound diverges into two-dimensional and three-dimensional agent variants, capitalizing on real-time imaging dynamics. On the application front, cardiology and oncology remain the most active segments, yet gastroenterology, musculoskeletal, and neurology procedures are fueling incremental uptake. End user profiles span academic research institutes to ambulatory surgical centers, diagnostic laboratories, and hospitals and imaging centers. Distribution channels encompass direct sales teams, international and local distributors, and emerging online retail platforms that are reshaping customer engagement and fulfillment models.
Deciphering Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific to Reveal Growth Drivers and Strategic Investment Hotspots
Regional dynamics offer a nuanced perspective on where demand, innovation, and infrastructure converge to create competitive advantages. In the Americas, advanced healthcare systems and established reimbursement pathways support rapid adoption of high-end contrast media and radiopharmaceutical agents. North American research hubs continue to pioneer novel tracer development, while Latin American markets are investing in capacity expansion to broaden patient access.
In Europe, Middle East & Africa, a patchwork of regulatory regimes and reimbursement policies influences launch strategies and pricing. Western European nations maintain stringent approval processes balanced by structured market access programs, whereas Gulf Cooperation Council countries are investing heavily in nuclear imaging infrastructure. Africa presents emerging opportunities for portable ultrasound contrast agents in regions underserved by centralized imaging facilities. Across the Asia-Pacific, robust population growth, improving healthcare expenditure, and local manufacturing initiatives are driving dynamic uptake. From established economies in Japan and Australia to rapidly expanding markets in China and India, stakeholders are tailoring portfolios to align with regional epidemiology and resource availability.
Analyzing Competitive Strategies and Innovation Benchmarks of Leading Market Players Driving Technological Leadership and Portfolio Differentiation in Imaging Agent Development
Leading stakeholders in the imaging agents domain are leveraging robust R&D pipelines, strategic alliances, and targeted acquisitions to maintain competitive differentiation. Established multinationals are prioritizing molecular innovation and supply chain integration, while nimble biotechs are capitalizing on niche therapeutic areas and orphan indications. Collaborative ventures between major healthcare conglomerates and specialized tracer developers are expediting clinical trials and broadening geographic reach.
Companies are also emphasizing portfolio diversification, balancing traditional contrast media lines with emerging microbubble and radiopharmaceutical offerings. The integration of digital platforms for remote training, quality assurance, and predictive maintenance enhances customer engagement and fosters long-term loyalty. Intellectual property strategies center on novel chelates, biodegradable carriers, and advanced radiolabeling methodologies. As competitive intensity intensifies, the ability to align technological prowess with market access acumen will define leadership positions.
Implementing Strategic Imperatives for Industry Leaders to Leverage Emerging Imaging Agent Technologies Optimize Supply Networks and Expand Global Footprint
To capitalize on emerging opportunities, industry leaders should accelerate investments in artificial intelligence-enabled agent design and predictive analytics. Establishing cross-functional teams that integrate chemistry, data science, and regulatory expertise will shorten development timelines and enhance product profiles. At the same time, formalizing partnerships with contract manufacturing organizations and raw material suppliers can mitigate tariff risks and bolster supply chain agility.
Additionally, fostering collaborations with academic research institutes will unlock early‐stage discoveries and facilitate seamless translation to clinical practice. Embracing decentralized manufacturing models and localized production hubs will reduce lead times and support personalized medicine initiatives. Ultimately, organizations that align strategic prioritization with operational excellence and regulatory foresight will be best positioned to drive sustainable growth.
Applying Rigorous Research Methodologies Integrating Primary Interviews Secondary Data Analysis and Multi Layered Validation for Market Intelligence
This analysis is underpinned by a rigorous, multi-source research framework designed to deliver comprehensive market intelligence. Primary insights were garnered through in-depth interviews with key opinion leaders in radiology, nuclear medicine, and healthcare policy, supplemented by discussions with supply chain directors and commercial strategists. These first-hand perspectives provided actionable context on evolving clinical practices, sourcing challenges, and adoption barriers.
Secondary data collection encompassed peer-reviewed publications, regulatory filings, company financial reports, and public health databases. Through meticulous data synthesis and cross-validation, trends were corroborated and discrepancies resolved. The resulting narrative was subjected to multi-layered validation workshops with industry experts to ensure accuracy, relevance, and clarity. This structured approach ensures that the conclusions and recommendations presented herein rest on a solid evidentiary foundation.
Synthesizing Strategic and Analytical Insights to Navigate the Evolving Imaging Agents Landscape with Confidence Competitive Edge and Informed Decision Making
The imaging agents landscape is in the midst of a profound evolution, driven by converging technological, regulatory, and supply dynamics. From advanced contrast media formulations to precision radiopharmaceutical tracers, stakeholders face both unprecedented opportunities and complex challenges. Successful navigation requires a clear understanding of segmentation nuances, regional variances, and competitive imperatives.
By synthesizing transformative shifts, tariff impacts, segmentation insights, and best‐in‐class company strategies, this executive summary provides a cohesive roadmap for informed decision-making. Organizations that adopt a proactive stance-embracing innovation, fortifying supply chains, and forging strategic alliances-will secure a decisive advantage in this rapidly evolving arena.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Agent Type
Gadolinium Based Agents
Iodinated Contrast Agents
Microbubble Agents
Radiopharmaceuticals
Pet Imaging Agents
Spect Imaging Agents
Modality
Computed Tomography
Magnetic Resonance Imaging
Nuclear Imaging
Pet Imaging Agents
Spect Imaging Agents
Ultrasound Imaging
Three D Imaging Agents
Two D Imaging Agents
Application
Cardiology
Gastroenterology
Musculoskeletal
Neurology
Oncology
End User
Academic Research Institutes
Ambulatory Surgical Centers
Diagnostic Laboratories
Hospitals And Imaging Centers
Distribution Channel
Direct Sales
Distributors
International Distributors
Local Distributors
Online Retail
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
GE Healthcare
Bayer AG
Bracco Imaging S.p.A.
Guerbet S.A.
Lantheus Holdings, Inc.
Siemens Healthineers AG
Mallinckrodt plc
Fujifilm Holdings Corporation
Sagent Pharmaceuticals, Inc.
Cardinal Health, Inc.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of gallium-68 based PET tracers for neuroendocrine tumor imaging and theranostics
- 5.2. Advancements in ultra-high field MRI contrast agents targeting molecular biomarkers in oncology research
- 5.3. Growth of multimodal imaging agents combining optical and nuclear labels for intraoperative cancer detection
- 5.4. Regulatory approvals accelerating commercialization of PSMA-targeted radiotracers in prostate cancer diagnostics
- 5.5. Development of nanoparticle-based contrast agents enabling targeted delivery and reduced toxicity in cardiovascular imaging
- 5.6. Increasing investment in fluorine-18 labeled tracers for routine clinical PET applications in neurology and cardiology
- 5.7. Emergence of bioengineered enzyme-activated imaging probes for real-time monitoring of inflammatory disease progression
- 5.8. Collaborations between pharmaceutical companies and academic institutions to streamline radiochemistry supply chains
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Imaging Agents Market, by Agent Type
- 8.1. Gadolinium Based Agents
- 8.2. Iodinated Contrast Agents
- 8.3. Microbubble Agents
- 8.4. Radiopharmaceuticals
- 8.4.1. Pet Imaging Agents
- 8.4.2. Spect Imaging Agents
- 9. Imaging Agents Market, by Modality
- 9.1. Computed Tomography
- 9.2. Magnetic Resonance Imaging
- 9.3. Nuclear Imaging
- 9.3.1. Pet Imaging Agents
- 9.3.2. Spect Imaging Agents
- 9.4. Ultrasound Imaging
- 9.4.1. Three D Imaging Agents
- 9.4.2. Two D Imaging Agents
- 10. Imaging Agents Market, by Application
- 10.1. Cardiology
- 10.2. Gastroenterology
- 10.3. Musculoskeletal
- 10.4. Neurology
- 10.5. Oncology
- 11. Imaging Agents Market, by End User
- 11.1. Academic Research Institutes
- 11.2. Ambulatory Surgical Centers
- 11.3. Diagnostic Laboratories
- 11.4. Hospitals And Imaging Centers
- 12. Imaging Agents Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Distributors
- 12.2.1. International Distributors
- 12.2.2. Local Distributors
- 12.3. Online Retail
- 13. Imaging Agents Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Imaging Agents Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Imaging Agents Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. GE Healthcare
- 16.3.2. Bayer AG
- 16.3.3. Bracco Imaging S.p.A.
- 16.3.4. Guerbet S.A.
- 16.3.5. Lantheus Holdings, Inc.
- 16.3.6. Siemens Healthineers AG
- 16.3.7. Mallinckrodt plc
- 16.3.8. Fujifilm Holdings Corporation
- 16.3.9. Sagent Pharmaceuticals, Inc.
- 16.3.10. Cardinal Health, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
